Renal neuroendocrine tumours: A clinicopathological study

Brian R. Lane, Farah Chery, George Jour, Linda Sercia, Cristina Magi-Galluzzi, Andrew C. Novick, Ming Zhou

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

OBJECTIVES: To report cases of primary neuroendocrine tumours (NETs) of the kidney, including carcinoid tumour, large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC), which show a wide range of NE differentiation and biological behaviour, and are exceedingly rare. PATIENTS AND METHODS: The clinicopathological features of all nine renal NETs diagnosed during a 7-year period were reviewed. RESULTS: Six carcinoids, two SCC and one LCNEC were identified from 2780 kidney tumours. No patient had carcinoid syndrome or other NE symptoms. Three of six carcinoids and no SCC/LCNEC arose in horseshoe kidneys. The mean size of the six carcinoids and three SCC/LCNEC was 4.8 cm and 12.2 cm, respectively. No carcinoid had tumour necrosis or mitosis. By contrast, three SCC/LCNEC had extensive tumour necrosis and brisk mitosis. All renal NETs were positive for synaptophysin but were variably positive for chromogranin and CD56. Three of six carcinoid tumours were confined to the kidney, and four of five patients were disease-free at a mean (range) of 26 (6-74) months. One patient with nodal metastases has had no recurrence and another died with liver metastases. Three patients with SCC/LCNEC each presented with locally advanced disease and extensive lymphadenopathy; two of them died from distant metastasis or local tumour progression, and the third is currently alive with disease. CONCLUSIONS: Various NETs can occur in the kidney, but rarely. Renal carcinoids have a variable clinical course; SCC and LCNEC are associated with poor clinical outcomes. The diagnosis of NETs, especially LCNEC, requires awareness of their rare occurrence and prudent use of immunohistochemical NE markers.

Original languageEnglish (US)
Pages (from-to)1030-1035
Number of pages6
JournalBJU International
Volume100
Issue number5
DOIs
StatePublished - Nov 1 2007

Fingerprint

Neuroendocrine Carcinoma
Large Cell Carcinoma
Neuroendocrine Tumors
Carcinoid Tumor
Small Cell Carcinoma
Kidney
Neoplasm Metastasis
Mitosis
Necrosis
Chromogranins
Neoplasms
Synaptophysin
Recurrence
Liver

Keywords

  • Carcinoid
  • Kidney neoplasm
  • Large-cell
  • Metastasis
  • Neuroendocrine tumour
  • Small cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Lane, B. R., Chery, F., Jour, G., Sercia, L., Magi-Galluzzi, C., Novick, A. C., & Zhou, M. (2007). Renal neuroendocrine tumours: A clinicopathological study. BJU International, 100(5), 1030-1035. https://doi.org/10.1111/j.1464-410X.2007.07116.x

Renal neuroendocrine tumours : A clinicopathological study. / Lane, Brian R.; Chery, Farah; Jour, George; Sercia, Linda; Magi-Galluzzi, Cristina; Novick, Andrew C.; Zhou, Ming.

In: BJU International, Vol. 100, No. 5, 01.11.2007, p. 1030-1035.

Research output: Contribution to journalArticle

Lane, BR, Chery, F, Jour, G, Sercia, L, Magi-Galluzzi, C, Novick, AC & Zhou, M 2007, 'Renal neuroendocrine tumours: A clinicopathological study', BJU International, vol. 100, no. 5, pp. 1030-1035. https://doi.org/10.1111/j.1464-410X.2007.07116.x
Lane BR, Chery F, Jour G, Sercia L, Magi-Galluzzi C, Novick AC et al. Renal neuroendocrine tumours: A clinicopathological study. BJU International. 2007 Nov 1;100(5):1030-1035. https://doi.org/10.1111/j.1464-410X.2007.07116.x
Lane, Brian R. ; Chery, Farah ; Jour, George ; Sercia, Linda ; Magi-Galluzzi, Cristina ; Novick, Andrew C. ; Zhou, Ming. / Renal neuroendocrine tumours : A clinicopathological study. In: BJU International. 2007 ; Vol. 100, No. 5. pp. 1030-1035.
@article{ce5d765283be43b2859b21fd6bd107f6,
title = "Renal neuroendocrine tumours: A clinicopathological study",
abstract = "OBJECTIVES: To report cases of primary neuroendocrine tumours (NETs) of the kidney, including carcinoid tumour, large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC), which show a wide range of NE differentiation and biological behaviour, and are exceedingly rare. PATIENTS AND METHODS: The clinicopathological features of all nine renal NETs diagnosed during a 7-year period were reviewed. RESULTS: Six carcinoids, two SCC and one LCNEC were identified from 2780 kidney tumours. No patient had carcinoid syndrome or other NE symptoms. Three of six carcinoids and no SCC/LCNEC arose in horseshoe kidneys. The mean size of the six carcinoids and three SCC/LCNEC was 4.8 cm and 12.2 cm, respectively. No carcinoid had tumour necrosis or mitosis. By contrast, three SCC/LCNEC had extensive tumour necrosis and brisk mitosis. All renal NETs were positive for synaptophysin but were variably positive for chromogranin and CD56. Three of six carcinoid tumours were confined to the kidney, and four of five patients were disease-free at a mean (range) of 26 (6-74) months. One patient with nodal metastases has had no recurrence and another died with liver metastases. Three patients with SCC/LCNEC each presented with locally advanced disease and extensive lymphadenopathy; two of them died from distant metastasis or local tumour progression, and the third is currently alive with disease. CONCLUSIONS: Various NETs can occur in the kidney, but rarely. Renal carcinoids have a variable clinical course; SCC and LCNEC are associated with poor clinical outcomes. The diagnosis of NETs, especially LCNEC, requires awareness of their rare occurrence and prudent use of immunohistochemical NE markers.",
keywords = "Carcinoid, Kidney neoplasm, Large-cell, Metastasis, Neuroendocrine tumour, Small cell carcinoma",
author = "Lane, {Brian R.} and Farah Chery and George Jour and Linda Sercia and Cristina Magi-Galluzzi and Novick, {Andrew C.} and Ming Zhou",
year = "2007",
month = "11",
day = "1",
doi = "10.1111/j.1464-410X.2007.07116.x",
language = "English (US)",
volume = "100",
pages = "1030--1035",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Renal neuroendocrine tumours

T2 - A clinicopathological study

AU - Lane, Brian R.

AU - Chery, Farah

AU - Jour, George

AU - Sercia, Linda

AU - Magi-Galluzzi, Cristina

AU - Novick, Andrew C.

AU - Zhou, Ming

PY - 2007/11/1

Y1 - 2007/11/1

N2 - OBJECTIVES: To report cases of primary neuroendocrine tumours (NETs) of the kidney, including carcinoid tumour, large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC), which show a wide range of NE differentiation and biological behaviour, and are exceedingly rare. PATIENTS AND METHODS: The clinicopathological features of all nine renal NETs diagnosed during a 7-year period were reviewed. RESULTS: Six carcinoids, two SCC and one LCNEC were identified from 2780 kidney tumours. No patient had carcinoid syndrome or other NE symptoms. Three of six carcinoids and no SCC/LCNEC arose in horseshoe kidneys. The mean size of the six carcinoids and three SCC/LCNEC was 4.8 cm and 12.2 cm, respectively. No carcinoid had tumour necrosis or mitosis. By contrast, three SCC/LCNEC had extensive tumour necrosis and brisk mitosis. All renal NETs were positive for synaptophysin but were variably positive for chromogranin and CD56. Three of six carcinoid tumours were confined to the kidney, and four of five patients were disease-free at a mean (range) of 26 (6-74) months. One patient with nodal metastases has had no recurrence and another died with liver metastases. Three patients with SCC/LCNEC each presented with locally advanced disease and extensive lymphadenopathy; two of them died from distant metastasis or local tumour progression, and the third is currently alive with disease. CONCLUSIONS: Various NETs can occur in the kidney, but rarely. Renal carcinoids have a variable clinical course; SCC and LCNEC are associated with poor clinical outcomes. The diagnosis of NETs, especially LCNEC, requires awareness of their rare occurrence and prudent use of immunohistochemical NE markers.

AB - OBJECTIVES: To report cases of primary neuroendocrine tumours (NETs) of the kidney, including carcinoid tumour, large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC), which show a wide range of NE differentiation and biological behaviour, and are exceedingly rare. PATIENTS AND METHODS: The clinicopathological features of all nine renal NETs diagnosed during a 7-year period were reviewed. RESULTS: Six carcinoids, two SCC and one LCNEC were identified from 2780 kidney tumours. No patient had carcinoid syndrome or other NE symptoms. Three of six carcinoids and no SCC/LCNEC arose in horseshoe kidneys. The mean size of the six carcinoids and three SCC/LCNEC was 4.8 cm and 12.2 cm, respectively. No carcinoid had tumour necrosis or mitosis. By contrast, three SCC/LCNEC had extensive tumour necrosis and brisk mitosis. All renal NETs were positive for synaptophysin but were variably positive for chromogranin and CD56. Three of six carcinoid tumours were confined to the kidney, and four of five patients were disease-free at a mean (range) of 26 (6-74) months. One patient with nodal metastases has had no recurrence and another died with liver metastases. Three patients with SCC/LCNEC each presented with locally advanced disease and extensive lymphadenopathy; two of them died from distant metastasis or local tumour progression, and the third is currently alive with disease. CONCLUSIONS: Various NETs can occur in the kidney, but rarely. Renal carcinoids have a variable clinical course; SCC and LCNEC are associated with poor clinical outcomes. The diagnosis of NETs, especially LCNEC, requires awareness of their rare occurrence and prudent use of immunohistochemical NE markers.

KW - Carcinoid

KW - Kidney neoplasm

KW - Large-cell

KW - Metastasis

KW - Neuroendocrine tumour

KW - Small cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=35148857713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148857713&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2007.07116.x

DO - 10.1111/j.1464-410X.2007.07116.x

M3 - Article

C2 - 17784891

AN - SCOPUS:35148857713

VL - 100

SP - 1030

EP - 1035

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 5

ER -